185 related articles for article (PubMed ID: 36922937)
21. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
Joshi Y; Sória MG; Quadrato G; Inak G; Zhou L; Hervera A; Rathore KI; Elnaggar M; Cucchiarini M; Marine JC; Puttagunta R; Di Giovanni S
Brain; 2015 Jul; 138(Pt 7):1843-62. PubMed ID: 25981963
[TBL] [Abstract][Full Text] [Related]
22. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
23. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Verstovsek S; Al-Ali HK; Mascarenhas J; Perkins A; Vannucchi AM; Mohan SR; Scott BL; Woszczyk D; Koschmieder S; García-Delgado R; László R; McGreivy JS; Rothbaum WP; Kiladjian JJ
Future Oncol; 2022 Nov; ():. PubMed ID: 36416118
[TBL] [Abstract][Full Text] [Related]
24. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.
Dar AA; Majid S; Rittsteuer C; de Semir D; Bezrookove V; Tong S; Nosrati M; Sagebiel R; Miller JR; Kashani-Sabet M
J Natl Cancer Inst; 2013 Mar; 105(6):433-42. PubMed ID: 23365201
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
26. FAM193A is a positive regulator of p53 activity.
Szwarc MM; Guarnieri AL; Joshi M; Duc HN; Laird MC; Pandey A; Khanal S; Dohm E; Bui AK; Sullivan KD; Galbraith MD; Andrysik Z; Espinosa JM
Cell Rep; 2023 Mar; 42(3):112230. PubMed ID: 36897777
[TBL] [Abstract][Full Text] [Related]
27. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
28. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.
Yi H; Yan X; Luo Q; Yuan L; Li B; Pan W; Zhang L; Chen H; Wang J; Zhang Y; Zhai Y; Qiu MZ; Yang DJ
J Exp Clin Cancer Res; 2018 May; 37(1):97. PubMed ID: 29716622
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
30. Mdm2 and Mdm4 loss regulates distinct p53 activities.
Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.
Yang H; Zheng Z; Zhao LY; Li Q; Liao D
Cell Cycle; 2012 Feb; 11(3):582-93. PubMed ID: 22262167
[TBL] [Abstract][Full Text] [Related]
33. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
34. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
[TBL] [Abstract][Full Text] [Related]
35. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.
Pant V; Xiong S; Iwakuma T; Quintás-Cardama A; Lozano G
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11995-2000. PubMed ID: 21730132
[TBL] [Abstract][Full Text] [Related]
36. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
37. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
38. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.
Christner SM; Clausen DM; Beumer JH; Parise RA; Guo J; Huang Y; Dömling AS; Eiseman JL
Cancer Chemother Pharmacol; 2015 Aug; 76(2):287-99. PubMed ID: 26050209
[TBL] [Abstract][Full Text] [Related]
39. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
40. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.
Canon J; Osgood T; Olson SH; Saiki AY; Robertson R; Yu D; Eksterowicz J; Ye Q; Jin L; Chen A; Zhou J; Cordover D; Kaufman S; Kendall R; Oliner JD; Coxon A; Radinsky R
Mol Cancer Ther; 2015 Mar; 14(3):649-58. PubMed ID: 25567130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
